Adília Hormigo
Corresponding Author: Adília Hormigo
MD, PhD, Department of Neurology
Memorial Sloan-Kettering Cancer Center
Name/email consistency: high
- Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Iwamoto, F.M., Hottinger, A.F., Karimi, S., Riedel, E., Dantis, J., Jahdi, M., Panageas, K.S., Lassman, A.B., Abrey, L.E., Fleisher, M., Deangelis, L.M., Holland, E.C., Hormigo, A. Neuro-oncology (2011)
- YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Hormigo, A., Gu, B., Karimi, S., Riedel, E., Panageas, K.S., Edgar, M.A., Tanwar, M.K., Rao, J.S., Fleisher, M., DeAngelis, L.M., Holland, E.C. Clin. Cancer Res. (2006)
- Nonconvulsive status epilepticus in patients with cancer: imaging abnormalities. Hormigo, A., Liberato, B., Lis, E., DeAngelis, L.M. Arch. Neurol. (2004)
- Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Hormigo, A., Abrey, L., Heinemann, M.H., DeAngelis, L.M. Br. J. Haematol. (2004)